Visit this portal to explore Alfa Cytology’s collection of brochures, posters and flyers. Sort by literature type or category to find the materials that best suit your needs.
Results:
As a committed preclinical research service provider focused on cancer, Alfa Ctytology’s one-stop drug discovery services and a range of technology platforms will address the diverse needs of our clients, guaranteeing innovative and effective research results.
Learn More
At Alfa Cytology, we offer a comprehensive suite of preclinical services tailored to advance cancer research and drug development. Our one-stop preclinical platform provides end-to-end solutions, from disease modeling and diagnostic development to therapeutic evaluation - all under one roof.
Learn More
Alfa Cytology is dedicated to delivering comprehensive services for cancer vaccine development and preclinical research, fostering groundbreaking advancements in cancer immunotherapy.
Learn More
Alfa Cytology offers comprehensive guidelines for the development of breast cancer 3D spheroid models, designed to support researchers in accurately simulating the tumor microenvironment.
Learn More
Alfa Cytology offers Single B Cell Technology, a cutting-edge platform for the discovery of antibodies, enabling the identification and development of highly specific and effective therapeutic antibodies.
Learn More
Personalized Cancer Vaccines are offered by Alfa Cytology through their cutting-edge Neoantigen Discovery services, aiming to improve the effectiveness of cancer treatment for our customers.
Downloads
Alfa Cytology offers a comprehensive, one-stop service dedicated to the development of innovative therapies for breast cancer, ensuring personalized treatment options and improving overall outcomes.
Learn More
Alfa Cytology has established a unique technology platform for neoantigen peptide synthesis, offering high-quality, microgram-sized products with a very short lead time (7-10 days) for neoantigen peptide synthesis.
Learn More
Comprehensive miRNA profiling in a DEN-induced mouse model identifies biomarkers linked to hepatocellular carcinoma, with Alfa Cytology facilitating their potential use in diagnosis and treatment development.
Learn More
Alfa Cytology offers Single B Cell Technology, a cutting-edge platform for the discovery of antibodies, enabling the identification and development of highly specific and effective therapeutic antibodies.
Learn More
Alfa Cytology was proud to participate in Cancer R&D 2024, where they presented a session titled "Designing Your Preclinical Cancer Modeling Mouse Studies," showcasing their expertise and innovative approaches in developing and optimizing mouse models for preclinical cancer research.
Learn More
When choosing the right service provider for cancer therapy development, it’s essential to consider factors like experience, expertise, and support. Alfa Cytology is here to guide you through this critical selection process.
Downloads
PARP inhibitors are a groundbreaking cancer therapy significantly improved by PDX models, which reliably replicate tumor characteristics and drug responses, with Alfa Cytology specializing in custom PDX models for PARP inhibitor development.
Learn More
Alfa Cytology offers a cutting-edge High-Throughput Screening (HTS) platform to accelerate the discovery and development of new drugs for pancreatic cancer treatment, enabling researchers to efficiently identify promising therapeutic candidates.
Downloads
Alfa Cytology specializes in comprehensive end-to-end solutions for the discovery and development of small molecular drugs targeting leukemia, ensuring advancements in treatment and improving patient outcomes through innovative research.
Downloads
Specializing in the development of TCR-T cell therapy aimed at targeting and fighting pancreatic cancer, Alfa Cytology provides innovative solutions within the field of cancer treatment and research.
Downloads
The Cell Line Derived Xenograft (CDX) model plays a crucial role in oncology research. At Alfa Cytology, we have mastered the art and science of CDX model development, offering a comprehensive range of services tailored to meet the diverse needs of our clients.
Downloads
Non-Coding RNAs are key regulators of many fundamental cellular processes, such as transcription, post-transcriptional modification, apoptosis, and cell metabolism. Therefore, dysregulation of ncRNAs plays an important role in the development of many diseases. Indeed, in a variety of cancers, ncRNAs are dysregulated either as oncogenic drivers or as tumor suppressors.
Learn More
Tumor biomarkers are molecules, genes, or proteins that reflect information about the presence, progression, and therapeutic efficacy of tumors, which have important applications in the diagnosis, therapy, and prognosis of cancer. Alfa Cytology is dedicated to providing cancer biomarker discovery and cancer diagnostic solutions based on individual customer needs.
Learn More
Alfa Cytology offers custom models that are a cut above the rest for effective solutions in cancer research. We have the capabilities to design and develop these models with meticulous attention to detail, catering to the specific demands of various cancer research projects and ultimately empowering researchers to achieve their goals.
Downloads
Alfa Cytology is committed to providing valuable insights on selecting appropriate in-vivo models for evaluating the effectiveness of cancer immunotherapy. Our skills assist in navigating the vast array of options, facilitating high-quality research in this crucial area of oncology.
Downloads
For those seeking a smooth preclinical R&D journey in cancer therapeutics, Alfa Cytology is the ideal partner. Our one-stop service combines all the essential elements, streamlining the development process. This integration not only makes the journey more efficient but also speeds up the pursuit of effective cancer treatments.
Downloads
When it comes to cancer diagnostic development, Alfa Cytology stands out. We are committed to delivering reliable services, using state-of-the-art techniques and a team of dedicated professionals. These services are designed to improve early detection and ultimately enhance patient outcomes.
Downloads
In the complex landscape of cancer therapeutics discovery and development, Alfa Cytology emerges as a trusted collaborator. We bring together cutting-edge technologies and a team of seasoned experts, enabling us to navigate every stage of the process, from initial concept exploration to advanced development.
Downloads
As your trusted preclinical partner in breast cancer therapeutics development, Alfa Cytology offers a unique blend of scientific acumen and industry experience. We navigate the complex landscape of preclinical research, ensuring that every step of your project is optimized for success.
Downloads
When it comes to prostate cancer research, our role as a full-services provider is unparalleled. We combine a team of world-class researchers with a diverse range of services, including biomarker discovery, pre-clinical model development, and translational research support, to drive your project forward with maximum efficiency.
Downloads
The 4T1 cell line is derived from spontaneous breast tumors in BALB/c mice and exhibits highly aggressive and tumorigenic behavior, closely resembling human breast cancer. Specifically, the 4T1 tumor models have been extensively studied for triple-negative breast cancer. Alfa Cytology provides mouse 4T1 models development services for breast cancer.
Downloads
Seprase, also known as fibroblast activation protein (FAP), is a serine protein hydrolase. It degrades the extracellular matrix and plays roles in cellular fenestration, fibrosis, wound healing, inflammation, and tumor growth. Whether optimizing small molecule probes or developing antibody-radionuclide conjugates, our one-stop solutions speed up your development project.
Downloads
The gut microbiota is vital for host health, and dysbiosis links to chronic diseases. In gastrointestinal cancer, it shows promise as biomarkers for predicting therapy responses. Alfa Cytology provides multi-omics analysis services to explore the gut microbiome’s role as a predictive biomarker for early colon cancer recurrence.
Learn More
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2025 Alfa Cytology. All rights reserved.
